Amylyx Pharmaceuticals, Inc. financial data

Symbol
AMLX on Nasdaq
Industry
Pharmaceutical Preparations
Location
43 Thorndike Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 486 % -38.1%
Quick Ratio 44.6 %
Debt-to-equity 24.9 % +68.2%
Return On Equity -85.4 % -17518%
Return On Assets -68.4 % -16112%
Operating Margin -139 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.5M shares +1.53%
Common Stock, Shares, Outstanding 68.5M shares +1.54%
Entity Public Float 1.31B USD +66.2%
Common Stock, Value, Issued 7K USD 0%
Weighted Average Number of Shares Outstanding, Basic 68.1M shares +1%
Weighted Average Number of Shares Outstanding, Diluted 68.1M shares -2.38%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 345K USD +21.1%
Revenue from Contract with Customer, Excluding Assessed Tax 196M USD -99.6%
Research and Development Expense 126M USD +18.9%
General and Administrative Expense 30M USD +292%
Costs and Expenses 469M USD +55.2%
Operating Income (Loss) -272M USD -3423%
Nonoperating Income (Expense) 14.7M USD +9.26%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -257M USD -4620%
Income Tax Expense (Benefit) 5.44M USD +1087%
Net Income (Loss) Attributable to Parent -259M USD -14232%
Earnings Per Share, Basic -3.82 USD/shares -7740%
Earnings Per Share, Diluted -3.82 USD/shares -19200%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 71.8M USD -46.9%
Marketable Securities, Current 163M USD
Accounts Receivable, after Allowance for Credit Loss, Current 1.73M USD -94.1%
Inventory, Net 38.3M USD +292%
Assets, Current 245M USD -43.5%
Property, Plant and Equipment, Net 1.25M USD -54.7%
Operating Lease, Right-of-Use Asset 2.28M USD -45.7%
Other Assets, Noncurrent 482K USD +1.26%
Assets 251M USD -46.3%
Accounts Payable, Current 1.49M USD -76.7%
Employee-related Liabilities, Current 15.2M USD +256%
Accrued Liabilities, Current 50.5M USD +36.2%
Liabilities, Current 53.9M USD +18.2%
Operating Lease, Liability, Noncurrent 595K USD -76.8%
Liabilities 54.5M USD +13.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 641K USD
Retained Earnings (Accumulated Deficit) -569M USD -83.8%
Stockholders' Equity Attributable to Parent 196M USD -53.1%
Liabilities and Equity 251M USD -46.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -489K USD +90.4%
Net Cash Provided by (Used in) Financing Activities 131K USD -87.4%
Net Cash Provided by (Used in) Investing Activities 819K USD -98.5%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 68.5M shares +1.54%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 351K USD -99.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 73.3M USD -46.1%
Deferred Tax Assets, Valuation Allowance 83.9M USD -7.36%
Deferred Tax Assets, Gross 85.5M USD -7.06%
Operating Lease, Liability 4.24M USD -32.5%
Depreciation 315K USD +54.4%
Payments to Acquire Property, Plant, and Equipment 67K USD -73.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -259M USD -10833%
Lessee, Operating Lease, Liability, to be Paid 4.54M USD -34.7%
Property, Plant and Equipment, Gross 4.31M USD +36.9%
Operating Lease, Liability, Current 1.97M USD -10.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.59M USD -36%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.48M USD +2.52%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 303K USD -55.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 476K USD -70%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.21M USD +118%
Lessee, Operating Lease, Liability, to be Paid, Year Four 476K USD
Operating Lease, Payments 100K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.55M USD +12.5%
Share-based Payment Arrangement, Expense 35.8M USD +6.27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%